NCT00395057View on ClinicalTrials.gov

A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

PHASE2TerminatedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

February 28, 2009

Conditions
Choroid NeovascularizationAge-Related Macular Degeneration
Interventions
DRUG

AGN 211745

AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2

DRUG

AGN 211745

AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2

DRUG

AGN 211745

AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2

DRUG

Ranibizumab 500µg

Ranibizumab 500µg injections at Day 1, Month 1, Month 2

Trial Locations (3)

Unknown

Houston

Sydney

Makati

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT00395057 - A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter